MK-3682B
Total Payments
$532,765
Transactions
174
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $325.00 | 1 | 0 |
| 2018 | $62,662 | 19 | 1 |
| 2017 | $469,778 | 154 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $532,765 | 174 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682B Grazoprevir,Ruzasvir,Uprifosbuvir in Participants with Chronic Hepatitis C Virus Genotype 3 Infection | Merck Sharp & Dohme Corporation | $326,754 | 1 |
| Extrahepatic Manifestations | Merck Sharp & Dohme Corporation | $105,911 | 0 |
| A Two Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3682B MK-3682,MK-5172,MK-8408 Fixed Dose Combination when Administered to Subjects with Moderate and Severe Renal Insufficiency | Merck Sharp & Dohme Corporation | $76,631 | 0 |
| A Phase II,III, Open-label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B MK-3682 Grazoprevir MK-8408 Fixed Dose Combination in Subjects with Chronic Hepatitis C Virus GT5 or GT6 Infection | Merck Sharp & Dohme Corporation | $23,469 | 0 |
Top Doctors Receiving Payments for MK-3682B
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $532,465 | 173 |
| , MD | Gastroenterology | Cleveland, OH | $300.00 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $532,765
Product Information
- Type Drug
- Total Payments $532,765
- Total Doctors 1
- Transactions 174
About MK-3682B
MK-3682B is a drug associated with $532,765 in payments to 1 healthcare providers, recorded across 174 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $325.00 was paid across 1 transactions to 0 doctors.
The most common payment nature for MK-3682B is "Unspecified" ($532,765, 100.0% of total).
MK-3682B is associated with 4 research studies, including "A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682B Grazoprevir,Ruzasvir,Uprifosbuvir in Participants with Chronic Hepatitis C Virus Genotype 3 Infection" ($326,754).